Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02533427
Registration number
NCT02533427
Ethics application status
Date submitted
24/08/2015
Date registered
26/08/2015
Date last updated
2/09/2020
Titles & IDs
Public title
Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol
Query!
Scientific title
A Phase 1, Open-Label, Drug Interaction Study Evaluating the Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol
Query!
Secondary ID [1]
0
0
GS-US-367-1909
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
HCV Infection
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - SOF/VEL/VOX
Treatment: Drugs - VOX
Treatment: Drugs - Norgestimate/ethinyl estradiol
Experimental: SOF/VEL/VOX + VOX - Part A: Participants without a documented history of taking norgestimate/ethinyl estradiol for at least one menstrual cycle will receive norgestimate/ethinyl estradiol. Participants with a documented history of taking norgestimate/ethinyl estradiol may enroll directly into Part B of the study.
Part B: Participants will continue taking norgestimate/ethinyl estradiol for the remainder of the study and will receive SOF/VEL/VOX FDC plus VOX.
Treatment: Drugs: SOF/VEL/VOX
400/100/100 mg FDC tablet administered orally once daily
Treatment: Drugs: VOX
100 mg tablet administered orally once daily
Treatment: Drugs: Norgestimate/ethinyl estradiol
Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Pharmacokinetic (PK) Parameter: AUCtau of Norelgestromin
Query!
Assessment method [1]
0
0
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Query!
Timepoint [1]
0
0
Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Primary outcome [2]
0
0
PK Parameter: AUCtau of Norgestrel
Query!
Assessment method [2]
0
0
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Query!
Timepoint [2]
0
0
Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Primary outcome [3]
0
0
PK Parameter: AUCtau of Ethinyl Estradiol
Query!
Assessment method [3]
0
0
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Query!
Timepoint [3]
0
0
Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Primary outcome [4]
0
0
Pharmacokinetic (PK) Parameter: AUCtau of Norgestimate
Query!
Assessment method [4]
0
0
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Query!
Timepoint [4]
0
0
Cycle 1,Study Day 14:Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Primary outcome [5]
0
0
PK Parameter: Cmax of Norelgestromin
Query!
Assessment method [5]
0
0
Cmax is defined as the maximum concentration of drug.
Query!
Timepoint [5]
0
0
Cycle 1,Study Day 14:Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Primary outcome [6]
0
0
PK Parameter: Cmax of Norgestrel
Query!
Assessment method [6]
0
0
Cmax is defined as the maximum concentration of drug.
Query!
Timepoint [6]
0
0
Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Primary outcome [7]
0
0
PK Parameter: Cmax of Ethinyl Estradiol
Query!
Assessment method [7]
0
0
Cmax is defined as the maximum concentration of drug.
Query!
Timepoint [7]
0
0
Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Primary outcome [8]
0
0
PK Parameter: Cmax of Norgestimate
Query!
Assessment method [8]
0
0
Cmax is defined as the maximum concentration of drug.
Query!
Timepoint [8]
0
0
Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Primary outcome [9]
0
0
PK Parameter: Ctau of Norelgestromin
Query!
Assessment method [9]
0
0
Ctau is defined as the observed drug concentration at the end of the dosing interval.
Query!
Timepoint [9]
0
0
Part A:Cycle 1,Study Day 14:Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Part B:Cycle 2,Study Day 42:Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Primary outcome [10]
0
0
PK Parameter: Ctau of Norgestrel
Query!
Assessment method [10]
0
0
Ctau is defined as the observed drug concentration at the end of the dosing interval.
Query!
Timepoint [10]
0
0
Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Primary outcome [11]
0
0
PK Parameter: Ctau of Ethinyl Estradiol
Query!
Assessment method [11]
0
0
Ctau is defined as the observed drug concentration at the end of the dosing interval.
Query!
Timepoint [11]
0
0
Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Primary outcome [12]
0
0
PK Parameter: Ctau of Norgestimate
Query!
Assessment method [12]
0
0
Ctau is defined as the observed drug concentration at the end of the dosing interval.
Query!
Timepoint [12]
0
0
Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose;Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Secondary outcome [1]
0
0
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
First dose date up to the last dose date (maximum: 84 days) plus 10 days
Query!
Secondary outcome [2]
0
0
Percentage of Participants Who Experienced Laboratory Abnormalities
Query!
Assessment method [2]
0
0
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Grade 1: mild; Grade 2: moderate;Grade 3: severe or medically significant but not immediately life-threatening; Grade 4: life-threatening consequences.
Query!
Timepoint [2]
0
0
First dose date up to the last dose date (maximum: 84 days) plus 10 days
Query!
Secondary outcome [3]
0
0
PK Parameter: Tmax of Norelgestromin, Norgestrel, Ethinyl Estradiol, and Norgestimate
Query!
Assessment method [3]
0
0
Tmax is defined as the time (observed time point) of Cmax.
Query!
Timepoint [3]
0
0
Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Secondary outcome [4]
0
0
PK Parameter: Tlast of Norelgestromin, Norgestrel, Ethinyl Estradiol, and Norgestimate
Query!
Assessment method [4]
0
0
Tlast is defined as the time (observed time point) of Clast.
Query!
Timepoint [4]
0
0
Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Secondary outcome [5]
0
0
PK Parameter: ?z of Norelgestromin, Norgestrel, Ethinyl Estradiol, and Norgestimate
Query!
Assessment method [5]
0
0
?z is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.
Query!
Timepoint [5]
0
0
Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42:Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Secondary outcome [6]
0
0
PK Parameter: t1/2 of Norelgestromin, Norgestrel, Ethinyl Estradiol, and Norgestimate
Query!
Assessment method [6]
0
0
t1/2 is defined as the estimate of the terminal elimination half-life of the drug.
Query!
Timepoint [6]
0
0
Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Secondary outcome [7]
0
0
PK Parameter: CLss/F Ethinyl Estradiol, and Norgestimate
Query!
Assessment method [7]
0
0
CLss/F is defined as the apparent steady state oral clearance following administration of the drug.
Query!
Timepoint [7]
0
0
\Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Secondary outcome [8]
0
0
PK Parameter: Cmax of Sofosbuvir (SOF), SOF Metabolites (GS-566500 and GS-331007), Velpatasvir (VEL), and Voxilaprevir (VOX)
Query!
Assessment method [8]
0
0
Cmax is defined as the maximum concentration of drug.
Query!
Timepoint [8]
0
0
Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Secondary outcome [9]
0
0
PK Parameter: Tmax of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX
Query!
Assessment method [9]
0
0
Tmax is defined as the time (observed time point) of Cmax.
Query!
Timepoint [9]
0
0
Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Secondary outcome [10]
0
0
PK Parameter: Tlast of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX
Query!
Assessment method [10]
0
0
Tlast is defined as the time (observed time point) of Clast.
Query!
Timepoint [10]
0
0
Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Secondary outcome [11]
0
0
PK Parameter: Ctau of SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX
Query!
Assessment method [11]
0
0
Ctau is defined as the observed drug concentration at the end of the dosing interval.
Query!
Timepoint [11]
0
0
Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Secondary outcome [12]
0
0
PK Parameter: ?z of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX
Query!
Assessment method [12]
0
0
?z is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.
Query!
Timepoint [12]
0
0
Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Secondary outcome [13]
0
0
PK Parameter: AUCtau of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX
Query!
Assessment method [13]
0
0
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Query!
Timepoint [13]
0
0
Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Secondary outcome [14]
0
0
PK Parameter: CLss/F of SOF, VEL, and VOX
Query!
Assessment method [14]
0
0
CLss/F is defined as the apparent steady state oral clearance following administration of the drug.
Query!
Timepoint [14]
0
0
Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Secondary outcome [15]
0
0
PK Parameter: t1/2 of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX
Query!
Assessment method [15]
0
0
t1/2 is defined as the estimate of the terminal elimination half-life of the drug.
Query!
Timepoint [15]
0
0
Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose
Query!
Eligibility
Key inclusion criteria
- Premenopausal female
- Must have a calculated body mass index (BMI) = 19.0 and = 30.0 kg/m^2 at screening
- Must have a negative serum pregnancy test at screening and urine pregnancy test at Day
-1
- Be willing and able to comply with all study requirements.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
45
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- Lactating female
- Have a history of any of the following:
- Significant drug sensitivity or drug allergy (such as anaphylaxis or
hepatoxicity)
- Known hypersensitivity to the study drugs, the metabolites or formulation
excipients
- Believed, by the study investigator, to be inappropriate for study participation for
any reason
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/10/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
18/03/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
15
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
Christchurch
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Gilead Sciences
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will evaluate the effect of sofosbuvir (SOF)/velpatasvir (VEL)/voxilaprevir (VOX)
fixed-dose combination (FDC) + voxilaprevir on the pharmacokinetics (PK) of a representative
hormonal contraceptive medication, norgestimate/ethinyl estradiol (Ortho Tri-Cyclen® Lo (OC))
and will assess the effect of norgestimate/ethinyl estradiol on the PK of SOF/VEL/VOX+VOX.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02533427
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Gilead Study Director
Query!
Address
0
0
Gilead Sciences
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02533427
Download to PDF